These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16284462)

  • 1. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.
    Verstuyft C; Marcellin F; Morand-Joubert L; Launay O; Brendel K; Mentré F; Peytavin G; Gérard L; Becquemont L; Aboulker JP;
    AIDS; 2005 Dec; 19(18):2127-31. PubMed ID: 16284462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
    AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V; Hocht C; Mangano A; Niselman V; Mariño Hernández E; Cáceres Guido P; Mecikovsky D; Bellusci C; Bologna R; Sen L; Rubio MC; Bramuglia GF
    Pharmacology; 2009; 83(1):59-66. PubMed ID: 19052483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
    Solas C; Simon N; Drogoul MP; Quaranta S; Frixon-Marin V; Bourgarel-Rey V; Brunet C; Gastaut JA; Durand A; Lacarelle B; Poizot-Martin I
    Br J Clin Pharmacol; 2007 Sep; 64(3):353-62. PubMed ID: 17517050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
    Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
    Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.
    Zhou XJ; Havlir DV; Richman DD; Acosta EP; Hirsch M; Collier AC; Tebas P; Sommadossi JP;
    AIDS; 2000 Dec; 14(18):2869-76. PubMed ID: 11153668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
    van Praag RM; Weverling GJ; Portegies P; Jurriaans S; Zhou XJ; Turner-Foisy ML; Sommadossi JP; Burger DM; Lange JM; Hoetelmans RM; Prins JM
    AIDS; 2000 Jun; 14(9):1187-94. PubMed ID: 10894283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB
    AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
    Bertrand J; Treluyer JM; Panhard X; Tran A; Auleley S; Rey E; Salmon-Céron D; Duval X; Mentré F;
    Eur J Clin Pharmacol; 2009 Jul; 65(7):667-78. PubMed ID: 19440701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.
    Saitoh A; Singh KK; Powell CA; Fenton T; Fletcher CV; Brundage R; Starr S; Spector SA
    AIDS; 2005 Mar; 19(4):371-80. PubMed ID: 15750390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.
    Cressey TR; Urien S; Hirt D; Halue G; Techapornroong M; Bowonwatanuwong C; Leenasirimakul P; Treluyer JM; Jourdain G; Lallemant M;
    Ther Drug Monit; 2011 Feb; 33(1):25-31. PubMed ID: 21233689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
    Rhame FS; Rawlins SL; Petruschke RA; Erb TA; Winchell GA; Wilson HM; Edelman JM; Abramson MA
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4200-8. PubMed ID: 15504842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART.
    Langmann P; Zilly M; Weissbrich B; Desch S; Väth T; Klinker H
    Infection; 2002 Jan; 30(1):13-6. PubMed ID: 11876509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
    Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
    Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
    Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.